

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Cormorant Asset Management, LP</u> (Last) (First) (Middle) 200 CLARENDON STREET, 52ND FLOOR (Street) BOSTON MA 02116 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Atea Pharmaceuticals, Inc. [AVIR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) Former 10% Owner
	3. Date of Earliest Transaction (Month/Day/Year) 11/03/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/03/2020		C		6,411,355	A	(1)	6,411,355	I	See Footnotes(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Convertible Preferred Stock	(1)	11/03/2020		C			1,000,000	(1)	(1)	Common Stock	1,000,000	(1)	0	I	See Footnotes(2)(4)
Series B Convertible Preferred Stock	(1)	11/03/2020		C			1,650,165	(1)	(1)	Common Stock	1,650,165	(1)	0	I	See Footnotes(2)(5)
Series C Convertible Preferred Stock	(1)	11/03/2020		C			2,631,580	(1)	(1)	Common Stock	2,631,580	(1)	0	I	See Footnotes(2)(6)
Series D Convertible Preferred Stock	(1)	11/03/2020		C			712,250	(1)	(1)	Common Stock	712,250	(1)	0	I	See Footnotes(2)(7)
Series D-1 Convertible Preferred Stock	(1)	11/03/2020		C			417,360	(1)	(1)	Common Stock	417,360	(1)	0	I	See Footnotes(2)(8)

1. Name and Address of Reporting Person* <u>Cormorant Asset Management, LP</u> (Last) (First) (Middle) 200 CLARENDON STREET, 52ND FLOOR (Street) BOSTON MA 02116 (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Chen Bihua</u> (Last) (First) (Middle) C/O CORMORANT ASSET MANAGEMENT, LLC 200 CLARENDON STREET, 52ND FLOOR (Street) BOSTON MA 02116 (City) (State) (Zip)
1. Name and Address of Reporting Person*

Cormorant Private Healthcare Fund II, LP

(Last) (First) (Middle)
200 CLARENDON STREET, 52ND FLOOR

(Street)
BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person *

Cormorant Global Healthcare Master Fund, LP

(Last) (First) (Middle)
200 CLARENDON STREET, 52ND FLOOR

(Street)
BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person *

CORMORANT PRIVATE HEALTHCARE FUND I, LP

(Last) (First) (Middle)
200 CLARENDON STREET, 52ND FLOOR

(Street)
BOSTON MA 02116

(City) (State) (Zip)

Explanation of Responses:

1. Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.
2. Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
3. Represents (i) 2,043,170 shares of Common Stock held by the Master Fund, (ii) 3,106,168 shares of Common Stock held by Fund I, (iii) 912,612 shares of Common Stock held by Fund II, and (iv) 349,405 shares of Common Stock held by the Account.
4. The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account.
5. The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account.
6. The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account.
7. The Series D Convertible Preferred Stock represented, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II.
8. The Series D-1 Convertible Preferred Stock represented, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II.

/s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP, By: Cormorant Global Healthcare GP, LLC, its General Partner, By: Bihua Chen, Managing Member 11/05/2020

/s/ CORMORANT ASSET MANAGEMENT, LP, By: Bihua Chen, Managing Member 11/05/2020

/s/ CORMORANT PRIVATE HEALTHCARE FUND II, LP By: Cormorant Private Healthcare GP II, LLC, its General Partner By: Bihua Chen, Managing Member 11/05/2020

/s/ Bihua Chen 11/05/2020

/s/ CORMORANT PRIVATE HEALTHCARE FUND I, LP By: Cormorant Private Healthcare GP, LLC, its General Partner By: Bihua Chen, Managing Member 11/05/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.